信迪利单抗对不同CEA表达水平食管癌患者的治疗效果  

Therapeutic effect of sintilimab on esophageal cancer patients with varying levels of carcinoembryonic antigen

作　　者：焦克 冯天明[1] 张万林 JIAO Ke;FENG Tianming;ZHANG Wanlin(Department of Oncology,Tianchang Hospital of Traditional Chinese Medicine,Anhui,Tianchang 239300,China)

机构地区：[1]安徽省天长市中医院肿瘤科,239300

出　　处：《河北医药》2024年第24期3721-3725,共5页Hebei Medical Journal

摘　　要：目的分析信迪利单抗对不同癌胚抗原(CEA)表达水平的食管癌患者治疗效果的影响。方法选取2020年1月至2024年1月收治的86例食管癌患者为研究对象,以CEA表达水平3.65 ng/mL为临界值,将CEA>3.65 ng/mL的43例患者作为对照组,CEA≤3.65 ng/mL的43例患者作为研究组,2组患者均采用信迪利单抗治疗。检测对比2组临床疗效、细胞免疫功能、肿瘤标志物、应激激素、预后指标。结果与对照组相比,研究组临床疗效较好(P<0.05)。治疗后2组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、心肌肌钙蛋白I(cTnI)、B型钠尿肽(BNP)水平、Karnofsky评分、SF-36评分升高,且研究组较高(P<0.05)。治疗后2组血红蛋白、白蛋白、前白蛋白、L3骨骼肌质量指数、细胞角质蛋白19片段(CYFRA21-1)、糖类抗原199(CA199)、糖类抗原125(CA125)、生长激素(GH)、催乳素(PRL)、碱性成纤维细胞生长因子(bFGF)、胰岛素样生长因子1(IGF-1)水平降低,且研究组较低(P<0.05)。结论食管癌患者采用信迪利单抗治疗,具有较好的效果,且相对于CEA高表达的患者,信迪利单抗对CEA低表达患者治疗效果较好,可降低肿瘤标志物水平,改善患者免疫功能、预后,促使患者的恢复。Objective To analyze the therapeutic effect of sintilimab on esophageal cancer patients with varying levels of carcinoembryonic antigen(CEA).Methods A total of 86 esophageal cancer patients admitted from January 2020 to January 2024 were selected as the study subjects.With the threshold of CEA at 3.65ng/mL,43 patients with CEA>3.65ng/mL were selected as the control group,and 43 patients with CEA≤3.65ng/mL were selected as the study group.Both groups of patients were treated with sintilimab.Clinical efficacy,cellular immune function,tumor markers,stress hormones,and prognostic indicators were compared between two groups.Results Compared with those of the control group,patients in the study group had a better clinical efficacy(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+),cardiac troponin I(cTnI),B-type natriuretic peptide(BNP),the Karnofsky Performance Scale(KPS)score,and 36-Item Short-Form Survey(SF-36)score significantly increased in both groups,and they were significantly higher in the study group(P<0.05).After treatment,the levels of hemoglobin,albumin,prealbumin,L3 skeletal muscle mass index,cytokeratin 19 fragment(CYFRA21-1),carbohydrate antigen 199(CA199),carbohydrate antigen 125(CA125),growth hormone(GH),prolactin(PRL),basic fibroblast growth factor(bFGF),and insulin-like growth factor 1(IGF-1)significantly decreased in both groups,and they were significantly lower in the study group(P<0.05).Conclusion Esophageal cancer patients treated with sintilimab have a good efficacy.Compared to those with high CEA expression,sintilimab has a better therapeutic effect on esophageal cancer patients with low CEA expression.It can reduce tumor marker levels,improve the immune function,prognosis,and recovery.

关 键 词：食管癌 信迪利单抗 癌胚抗原 肿瘤标志物 

分 类 号：R735.1[医药卫生—肿瘤]